Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glioblastoma Multiforme

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    115 result(s) found for: Glioblastoma Multiforme. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2009-018258-43 Sponsor Protocol Number: 327/09 Start Date*: 2009-09-16
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: SIB-GBM trial (Simultaneous Integrated Boost in Glioblastoma multiforme: hyprofractionated radiotherapy with concomitant boost and temozolomide, in glioblastoma RPA III and IV patients
    Medical condition: patients affected by glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001664-50 Sponsor Protocol Number: DS/04/FTMS/01 Start Date*: 2005-02-04
    Sponsor Name:ITALFARMACO
    Full Title: An open label, phase II multicentre evaluation of the activity and safety of fotemustine administered to patients with recurrent or progressive glioblastoma multiforme.
    Medical condition: Recurrent or progressive glioblastoma multiforme after radiotherapy and adjuvant chemiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    10018337 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001763-11 Sponsor Protocol Number: STUDIO GLIMESOR – ASL608LIOM02 Start Date*: 2008-07-09
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: LOW-DOSE METRONOMIC TEMOZOLOMIDE AND SORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: A PHASE II CLINICAL TRIAL WITH EVALUATION OF CLINICAL, BIOLOGIC AND PHARMACODYNAMIC EFFECTS OF TH...
    Medical condition: PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 LLT
    9.1 10018337 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004138-42 Sponsor Protocol Number: CLP1000080 Start Date*: 2006-01-23
    Sponsor Name:BRAINSGATE LTD
    Full Title: A multicenter prospective study Safety and feasibility of NeuropathTM Activation during chemiotherapy on Inoperable and Recurrent Glioblastoma Multiforme Patients
    Medical condition: Recurrent Glioblastoam multiforme
    Disease: Version SOC Term Classification Code Term Level
    10018337 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021407-24 Sponsor Protocol Number: BIBF1120-GBM Start Date*: 2010-11-09
    Sponsor Name:Rigshospitalet
    Full Title: Phase II study of BIBF 1120 in recurrent Glioblastoma multiforme
    Medical condition: Relapsed glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-013662-33 Sponsor Protocol Number: GICNO 08.001 Start Date*: 2009-12-04
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: PROSPECTIVE EVALUATION OF SERUM MALDI TOF MS PROTEOMIC PROFILE PREDICTIVE OF OUTCOME IN PATIENTS WITH GLIOBLASTOMA MULTIFORME TREATED WITH STANDARD TREATMENT STRATIFIED ACCORDING TO MGMT
    Medical condition: patients affected by GBM
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003545-11 Sponsor Protocol Number: DNOG-LOBE-01 Start Date*: 2020-12-16
    Sponsor Name:Rigshospitalet
    Full Title: A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma.
    Medical condition: recurrent glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-018228-14 Sponsor Protocol Number: S52111 Start Date*: 2011-07-14
    Sponsor Name:University Hospital Leuven
    Full Title: HGG-2010. AS phase IIb prospective placebo-controlled double blind randomized clinical trial for the treatment of patients with newly diagnosed glioblastoma multiforme with tumor vaccination as "ad...
    Medical condition: Patients with newly diagnosed glioblastoma which can be resected up to a (sub)total extent.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000700-38 Sponsor Protocol Number: TEM-LT Start Date*: 2021-07-12
    Sponsor Name:GENENTA SCIENCE SRL
    Full Title: A follow-up study evaluating the long term safety of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-a2 gene...
    Medical condition: Glioblastoma multiforme (GBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001980-41 Sponsor Protocol Number: CSTI571BDE66 Start Date*: 2007-02-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Glivec® (imatinib mesylate)/Litalir® (hydroxyurea) plus initial radiotherapy after surgery in patients with newly diagnosed glioblastoma multiforme followed by Glivec® and Litalir® – A phase I/II s...
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001104-21 Sponsor Protocol Number: ND-05006 Start Date*: 2009-01-28
    Sponsor Name:VU Cancer Centre, Afdeling Geneeskundige Oncologie
    Full Title: A PHASE I/II TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS (DELTA-24-RGD) ADMINISTERED BY CONVECTION ENHANCED DELIVERY IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME
    Medical condition: Recurrent Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000572-33 Sponsor Protocol Number: ParvOryx01 Start Date*: 2011-09-02
    Sponsor Name:Oryx GmbH und Co. KG
    Full Title: Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of PArvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003679-40 Sponsor Protocol Number: BEV-CCI-779-GBM-02 Start Date*: 2008-09-03
    Sponsor Name:Rigshospitalet
    Full Title: A phase II study of temsirolimus and bevacizumab in recurrent glioblastoma multiforme
    Medical condition: Glioblastoma multiforme and progression after prior VEGF-directed therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001144-39 Sponsor Protocol Number: GBMBIBT01 Start Date*: 2008-08-12
    Sponsor Name:Rigshospitalet
    Full Title: A randomized phase II trial with bevacizumab, irinotecan and cerebral radiotherapy versus bevacizumab, temozolomide and cerebral radiotherapy as first line treatment for patients with glioblastoma ...
    Medical condition: This study investigates first line experimental non-surgical therapy in patients with glioblastoma multiforme in good performance status
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-009879-35 Sponsor Protocol Number: DEND/GM Start Date*: 2009-09-03
    Sponsor Name:Instituto Científico y Tecnológico de Navarra, S.A.
    Full Title: Estudio prospectivo en fase II de la eficacia y seguridad de la vacunación con células dendríticas autólogas en pacientes con glioblastoma multiforme tras resección quirúrgica completa con microsco...
    Medical condition: Tratamiento de pacientes con glioblastoma multiforme con células dendríticas autólogas, tras resección quirúrgica completa con microscopio de fluorescencia
    Disease: Version SOC Term Classification Code Term Level
    9 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-001988-75 Sponsor Protocol Number: RACTAC Start Date*: 2019-10-22
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: REPURPOSING THE ANTIPSYCHOTIC DRUG CLORPROMAZINE AS A THERAPEUTIC AGENT IN THE COMBINED TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
    Medical condition: Newly diagnosed Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003127-41 Sponsor Protocol Number: BT009E Start Date*: 2021-05-12
    Sponsor Name:INSIGHTEC
    Full Title: Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) with Microbubble Resonators for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carbopla...
    Medical condition: Recurrent Glioblastoma (rGBM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015979-27 Sponsor Protocol Number: TRX2 Start Date*: 2010-02-25
    Sponsor Name:Activartis Biotech GmbH
    Full Title: First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells
    Medical condition: Patients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiati...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004344-78 Sponsor Protocol Number: EMD121974-011 Start Date*: 2008-08-28
    Sponsor Name:Merck KGaA
    Full Title: Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination wi...
    Medical condition: Newly diagnosed, histologically proven GBM with proven methylated MGMT gene promoter status
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) AT (Completed) DE (Completed) CZ (Completed) FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended) SK (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002417-21 Sponsor Protocol Number: AK2016-2 Start Date*: 2016-09-22
    Sponsor Name:Rigshospitalet
    Full Title: uPAR-PET/MR in glioma
    Medical condition: Gliomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 22:05:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA